Patents by Inventor Natarajan Muthusamy

Natarajan Muthusamy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING AND PREVENTING GRAFT VERSUS HOST DISEASE
    Publication number: 20230097340
    Abstract: Described herein are methods for treating and preventing graft versus host disease using ACK inhibitors. The methods include administering to an individual in need thereof an ACK inhibitor such as ibrutinib for treating and preventing graft versus host disease.
    Type: Application
    Filed: April 27, 2022
    Publication date: March 30, 2023
    Inventors: John C. Byrd, Jason A. Dubovsky, Natarajan Muthusamy, Amy J. Johnson, David Miklos
  • METHODS OF TREATING AND PREVENTING GRAFT VERSUS HOST DISEASE
    Publication number: 20210121463
    Abstract: Described herein are methods for treating and preventing graft versus host disease using ACK inhibitors. The methods include administering to an individual in need thereof an ACK inhibitor such as ibrutinib for treating and preventing graft versus host disease.
    Type: Application
    Filed: June 12, 2020
    Publication date: April 29, 2021
    Inventors: John C. Byrd, Jason A. Dubovsky, Natarajan Muthusamy, Amy J. Johnson, David Miklos
  • Methods of treating and preventing graft versus host disease
    Patent number: 10695350
    Abstract: Described herein are methods for treating and preventing graft versus host disease using ACK inhibitors. The methods include administering to an individual in need thereof an ACK inhibitor such as ibrutinib for treating and preventing graft versus host disease.
    Type: Grant
    Filed: September 25, 2019
    Date of Patent: June 30, 2020
    Assignee: Pharmacyclics LLC
    Inventors: John C. Byrd, Jason A. Dubovsky, Natarajan Muthusamy, Amy J. Johnson, David Miklos
  • TEC FAMILY KINASE INHIBITOR ADJUVANT THERAPY
    Publication number: 20200147084
    Abstract: Described herein are methods and compositions comprising a covalent TEC family kinase inhibitor for use in adjuvant therapy, including adjuvant cancer therapy, vaccination and treatment of immune disorders and pathogenic infections.
    Type: Application
    Filed: May 21, 2019
    Publication date: May 14, 2020
    Inventors: Joseph J. Buggy, Tarak D. Mody, John C. Byrd, Betty Y. Chang, Jason A. Dubovsky, Natarajan Muthusamy, Amy J. Johnson
  • METHODS OF TREATING AND PREVENTING GRAFT VERSUS HOST DISEASE
    Publication number: 20200009148
    Abstract: Described herein are methods for treating and preventing graft versus host disease using ACK inhibitors. The methods include administering to an individual in need thereof an ACK inhibitor such as ibrutinib for treating and preventing graft versus host disease.
    Type: Application
    Filed: September 25, 2019
    Publication date: January 9, 2020
    Inventors: John C. Byrd, Jason A. Dubovsky, Natarajan Muthusamy, Amy J. Johnson, David Miklos
  • TREATMENT OF CANCER USING ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20190388471
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a kinase inhibitor, e.g., a kinase inhibitor described herein. The invention also provides kits and compositions described herein.
    Type: Application
    Filed: June 7, 2019
    Publication date: December 26, 2019
    Applicants: Novartis AG, The Trustees of the University of Pennsylvania, The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, David L. Porter, Marcela Maus, Mariusz Wasik, Saar Gill, Joseph A. Fraietta, Marco Ruella, John Byrd, Jason Dubovsky, Amy Johnson, Natarajan Muthusamy, Saad Kenderian, Joan Mannick, David Jonathan Glass, Leon Murphy, Jennifer Brogdon, William Raj Sellers
  • Methods of treating and preventing graft versus host disease
    Patent number: 10463668
    Abstract: Described herein are methods for treating and preventing graft versus host disease using ACK inhibitors. The methods include administering to an individual in need thereof an ACK inhibitor such as ibrutinib for treating and preventing graft versus host disease.
    Type: Grant
    Filed: May 3, 2017
    Date of Patent: November 5, 2019
    Assignee: Pharmacyclics LLC
    Inventors: John C. Byrd, Jason A. Dubovsky, Natarajan Muthusamy, Amy J. Johnson, David Miklos
  • Treatment of cancer using anti-CD19 Chimeric Antigen Receptor
    Patent number: 10357514
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a kinase inhibitor, e.g., a kinase inhibitor described herein. The invention also provides kits and compositions described herein.
    Type: Grant
    Filed: April 7, 2015
    Date of Patent: July 23, 2019
    Assignees: The Trustees of the University of Pennsylvania, Novartis AG
    Inventors: Carl H. June, David L. Porter, Marcela Maus, Mariusz Wasik, Saar Gill, Joseph Fraietta, Marco Ruella, John Byrd, Jason Dubovsky, Amy Johnson, Natarajan Muthusamy, Saad Kenderian, Joan Mannick, David Glass, Leon Murphy, Jennifer Brogdon, William Raj Sellers
  • COMBINATION OF CHIMERIC ANTIGEN RECEPTOR THERAPY AND AMINO PYRIMIDINE DERIVATIVES
    Publication number: 20180140602
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a BTK inhibitor, e.g., an amino pyrimidine derivative described herein. The invention also provides kits and compositions described herein.
    Type: Application
    Filed: April 7, 2016
    Publication date: May 24, 2018
    Inventors: Daniela Angst, John Byrd, Jason Dubovsky, Joseph A. Fraietta, Francois Gessier, Saar Gill, Amy Johnson, Carl H. June, Marcela Maus, Natarajan Muthusamy, David L. Porter, Marco Ruella, Anna Vulpetti, Mariusz Wasik
  • METHODS OF TREATING AND PREVENTING GRAFT VERSUS HOST DISEASE
    Publication number: 20180078555
    Abstract: Described herein are methods for treating and preventing graft versus host disease using ACK inhibitors. The methods include administering to an individual in need thereof an ACK inhibitor such as ibrutinib for treating and preventing graft versus host disease.
    Type: Application
    Filed: May 3, 2017
    Publication date: March 22, 2018
    Inventors: John C. Byrd, Jason A. Dubovsky, Natarajan Muthusamy, Amy J. Johnson, David Miklos
  • TEC FAMILY KINASE INHIBITOR ADJUVANT THERAPY
    Publication number: 20180071293
    Abstract: Described herein are methods and compositions comprising a covalent TEC family kinase inhibitor for use in adjuvant therapy, including adjuvant cancer therapy, vaccination and treatment of immune disorders and pathogenic infections.
    Type: Application
    Filed: July 14, 2017
    Publication date: March 15, 2018
    Inventors: Joseph J. Buggy, Tarak D. Mody, Richard B. Love, John C. Byrd, Betty Y. Chang, Jason A. Dubovsky, Natarajan Muthusamy, Amy J. Johnson
  • Methods of treating and preventing graft versus host disease
    Patent number: 9795604
    Abstract: Described herein are methods for treating and preventing graft versus host disease using ACK inhibitors. The methods include administering to an individual in need thereof an ACK inhibitor such as ibrutinib for treating and preventing graft versus host disease.
    Type: Grant
    Filed: October 24, 2014
    Date of Patent: October 24, 2017
    Assignee: Pharmacyclics LLC
    Inventors: John C. Byrd, Jason A. Dubovsky, Natarajan Muthusamy, Amy Jo Johnson, David Miklos
  • TEC family kinase inhibitor adjuvant therapy
    Patent number: 9717731
    Abstract: Described herein are methods and compositions comprising a covalent TEC family kinase inhibitor for use in adjuvant therapy, including adjuvant cancer therapy, vaccination and treatment of immune disorders and pathogenic infections.
    Type: Grant
    Filed: November 1, 2013
    Date of Patent: August 1, 2017
    Assignee: Pharmacyclics LLC
    Inventors: Joseph J. Buggy, Tarak D. Mody, John C. Byrd, Betty Y. Chang, Jason A. Dubovsky, Natarajan Muthusamy, Amy Jo Johnson
  • TREATMENT OF CANCER USING ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20150283178
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a kinase inhibitor, e.g., a kinase inhibitor described herein. The invention also provides kits and compositions described herein.
    Type: Application
    Filed: April 7, 2015
    Publication date: October 8, 2015
    Inventors: Carl H. June, David L. Porter, Marcela Maus, Mariusz Wasik, Saar Gill, Joseph Fraietta, Marco Ruella, John Byrd, Jason Dubovsky, Amy Johnson, Natarajan Muthusamy, Saad Kenderian, Joan Mannick, David Glass, Leon Murphy, Jennifer Brogdon, William Raj Sellers
  • METHODS OF TREATING AND PREVENTING GRAFT VERSUS HOST DISEASE
    Publication number: 20150118209
    Abstract: Described herein are methods for treating and preventing graft versus host disease using ACK inhibitors. The methods include administering to an individual in need thereof an ACK inhibitor such as ibrutinib for treating and preventing graft versus host disease.
    Type: Application
    Filed: October 24, 2014
    Publication date: April 30, 2015
    Inventors: John C. BYRD, Jason A. DUBOVSKY, Natarajan MUTHUSAMY, Amy Jo JOHNSON, David MIKLOS
  • TEC FAMILY KINASE INHIBITOR ADJUVANT THERAPY
    Publication number: 20140371241
    Abstract: Described herein are methods and compositions comprising a covalent TEC family kinase inhibitor for use in adjuvant therapy, including adjuvant cancer therapy, vaccination and treatment of immune disorders and pathogenic infections.
    Type: Application
    Filed: March 5, 2014
    Publication date: December 18, 2014
    Applicant: Pharmacyclics, Inc.
    Inventors: Joseph J. BUGGY, Tarak D. Mody, Richard B. Love, John C. Byrd, Betty Chang, Jason A. Dubovsky, Natarajan Muthusamy, Amy Jo Johnson
  • FTY720 Increases CD74 Expression and Sensitizes Cancer Cells to Anti-CD74 Antibody-Mediated Cell Death
    Publication number: 20140056917
    Abstract: Disclosed herein are methods and compositions comprising fingolimod and anti-CD74 antibodies or fragments thereof. In preferred embodiments, the fingolimod increases the expression of CD74 in target cells and increases the sensitivity of the cells to the cytotoxic effects of the anti-CD74 antibodies. The compositions and methods are of use to treat diseases involving CD74+ cells, such as cancer cells, autoimmune disease cells or immune dysfunction disease cells.
    Type: Application
    Filed: October 22, 2013
    Publication date: February 27, 2014
    Applicants: IMMUNOMEDICS, INC., THE OHIO STATE UNIVERSITY
    Inventors: Lapo Alinari, Robert A. Baiocchi, Natarajan Muthusamy, Hans J. Hansen, David M. Goldenberg
  • Therapeutic agents for the treatment of leukemia
    Patent number: 8633161
    Abstract: The invention provides for methods of treating a mammal who has a BCR/ABL-mediated leukemia, including chronic myelogenous leukemia (CML), particularly the blast crisis stage of CML, Philadelphia-positive acute lymphoblastic leukemia (Ph?-ALL), and refractory leukemias. The invention also provides for compounds for the treatment of these leukemias and methods of identifying anti-leukemic agents.
    Type: Grant
    Filed: March 24, 2006
    Date of Patent: January 21, 2014
    Assignee: The Ohio State University Research Foundation
    Inventors: Danilo Perrotti, Paolo Neviani, Ramasamy Santhanam, John C. Byrd, Guido Marcucci, Natarajan Muthusamy, Ching-Shih Chen
  • FTY720 increases CD74 expression and sensitizes cancer cells to anti-CD74 antibody-mediated cell death
    Patent number: 8591892
    Abstract: Disclosed herein are methods and compositions comprising fingolimod and anti-CD74 antibodies or fragments thereof. In preferred embodiments, the fingolimod increases the expression of CD74 in target cells and increases the sensitivity of the cells to the cytotoxic effects of the anti-CD74 antibodies. The compositions and methods are of use to treat diseases involving CD74+ cells, such as cancer cells, autoimmune disease cells or immune dysfunction disease cells.
    Type: Grant
    Filed: July 18, 2012
    Date of Patent: November 26, 2013
    Assignees: The Ohio State University, Immunomedics, Inc.
    Inventors: Lapo Alinari, Robert A. Baiocchi, Natarajan Muthusamy, Hans J. Hansen, David M. Goldenberg
  • FTY720 Increases CD74 Expression and Sensitizes Cancer Cells to Anti-CD74 Antibody-Mediated Cell Death
    Publication number: 20130022541
    Abstract: Disclosed herein are methods and compositions comprising fingolimod and anti-CD74 antibodies or fragments thereof. In preferred embodiments, the fingolimod increases the expression of CD74 in target cells and increases the sensitivity of the cells to the cytotoxic effects of the anti-CD74 antibodies. The compositions and methods are of use to treat diseases involving CD74+ cells, such as cancer cells, autoimmune disease cells or immune dysfunction disease cells.
    Type: Application
    Filed: July 18, 2012
    Publication date: January 24, 2013
    Applicants: IMMUNOMEDICS, INC., THE OHIO STATE UNIVERSITY
    Inventors: Lapo Alinari, Robert A. Baiocchi, Natarajan Muthusamy, Hans J. Hansen, David M. Goldenberg